Financials data is unavailable for this security.
View more
Year on year Sunshine Guojian Pharmaceutical Shanghai Co Ltd grew revenues 22.84% from 825.49m to 1.01bn while net income improved 497.63% from 49.30m to 294.61m.
| Gross margin | 75.73% |
|---|---|
| Net profit margin | 28.72% |
| Operating margin | 33.16% |
| Return on assets | 6.36% |
|---|---|
| Return on equity | 7.39% |
| Return on investment | 6.97% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Sunshine Guojian Pharmaceutical Shanghai Co Ltd fell by 162.27m. However, the company earned 416.35m from its operations for a Cash Flow Margin of 41.06%. In addition the company used 479.42m on investing activities and also paid 101.47m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.23 |
|---|---|
| Tangible book value per share | 7.62 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.51 |
|---|---|
| Quick ratio | 3.24 |
| Total debt/total equity | 0.0099 |
|---|---|
| Total debt/total capital | 0.0098 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 497.60%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 14.07% |
| EPS growth(5 years) | -7.99 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 71.55 |
More ▼
